Summary

Report Details

The Direct-to-Patient Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Industry Focus on Patient-Centricity Is Driving the Market Growth
The direct-to-patient and home trial support (DtP/HTS) strategy can provide priceless assistance to patients, regardless of whether they are getting a commercial therapy that has been approved or are taking part in a clinical trial. The DtP strategy has developed over the past ten years, with global adoption expanding dramatically in the last three years, fuelled by an industry focus on patient-centricity that is becoming more intense. This strategy provides considerable benefits for the patient as well as all other parties by enabling patients to obtain individualised care, cutting-edge or well-established therapies without leaving the comfort of their own homes. Technology has changed every part of our everyday life, which makes the world feel smaller than it has ever been.

Businesses in the medical, healthcare, and pharmaceutical industries have refrained from embracing social media for a variety of reasons. Corporations welcomed it, but pharmacists baulked because they thought it would present an excessive amount of legal risk. Even so, a few forerunners in the direct-to-patient sector have prepared the way for others. They have demonstrated that, in the quickly evolving healthcare environment of today, it is not only doable but also crucial. Tens of thousands of branding exercises are sent to patients in the medical field each day.

What Questions Should You Ask before Buying a Market Research Report?
• How is the direct-to-patient (DTP) market evolving?
• What is driving and restraining the direct-to-patient (DTP) market?
• How will each direct-to-patient (DTP) submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each direct-to-patient (DTP) submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading direct-to-patient (DTP) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the direct-to-patient (DTP) projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of direct-to-patient (DTP) projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the direct-to-patient (DTP) market?
• Where is the direct-to-patient (DTP) market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the direct-to-patient (DTP) market today, and over the next 10 years:
• Our 344-page report provides 155 tables and 165 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the direct-to-patient (DTP) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising direct-to-patient (DTP) prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Type
• Direct-to-Patient Marketing
• Direct-to-Patient Health Services
• Direct-to-Patient Clinical Trials
• Direct-to-Patient Logistics

Direct-to-Patient Marketing
• DTC Prescribed Drug Advertising
• Disease Awareness Campaigns
• Brand Promotion
• Healthcare Services Promotion
• Laboratory Testing Promotion
• Other Direct-to-Patient Marketing

Direct-to-Patient Health Services
• Tele Consultation
• Drug Prescription
• Medical Call Centers
• Telesampling
• Online Services

Direct-to-Patient Clinical Trials
• Tele Health Screening
• Investigational Medicinal Product (IMP)
• Patient Support Systems
• Other Clinical Trial Services

Direct-to-Patient Logistics
• Prescribed Medicine Delivery
• Pre-Clinical Supplies
• Clinical Trial Supplies
• Home Trial Support
• Test Samples Collection
• Rest All CSO Services

Therapeutics
• Cardiovascular Disease
• Respiratory Diseases
• Oncology
• Infectious Diseases
• Dermatology
• Other Therapeutics

Model
• Depot-to-Patient
• Site-to-Patient
• Hybrid Model
• Direct-From-Patient (DfP)
• Other DtP Models

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

MEA
• Turkey
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA

Latin America
• Brazil
• Mexico
• Rest of Latin America

The report also includes profiles and for some of the leading companies in the Direct-to-Patient Market Report 2022-2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Access TeleCare
• Agnity Inc.
• AMD Global Telemedicine
• American Well
• Avel eCare
• Axs Health
• Babylon Health
• Citius Tech
• Dictum Health Inc.
• Doctor Anywhere
• Doctor on Demand
• Health Partners
• Health Tap
• HIMS
• Marken
• 20/20 NOW
• NURX
• Practo Technologies Pvt. Ltd.
• Specialists on call, Inc.
• Teladoc Health Inc.
• True pill
• Up Script Health

Overall world revenue for Direct-to-Patient (DTP) Market, 2022 to 2032 in terms of value the market will surpass US$40,746 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Direct-to-Patient Market Report 2022-2032 report help you?
In summary, our 340+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Direct-to-Patient (DTP) Market, 2022 to 2032 Market, with forecasts for type, direct-to-patient marketing, direct-to-patient health services, clinical trials, direct-to-patient logistics, therapeutics, and model, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and 20 key national markets – See forecasts for the Direct-to-Patient (DTP) Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 22 of the major companies involved in the Direct-to-Patient (DTP) Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Direct-to-Patient (DTP) Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

Table of Contents

1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Direct-To-Patient Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increase in Social Media's Relevance
3.2.1.2 Direct-to-Patient Marketing Driven by Decentralization
3.2.1.3 Recognizing the Value of Direct-to-Patient
3.2.2 Market Restraining Factors
3.2.2.1 Legal restrictions Are Impeding the Expansion of the DTP Market
3.2.2.2 Development of Digital Technology Projected to Boost Industry Growth
3.2.2.3 Booming Telehealth to Fuel Market Growth
3.2.3 Market Opportunities
3.2.3.1 DTP Services Are not Just for Delivering Medications
3.2.3.2 DTP Would be the Primary Point of Contact for Patient Support
3.2.3.3 DTP's Integration into Medical Universities, Clinics, and Hospitals
3.3 Supply Chain
3.4 COVID-19 Impact Analysis
3.4.1 COVID Impact Market Analysis (V-Shaped Recovery Scenario)
3.4.2 COVID Impact Market Analysis (W-Shaped Recovery Scenario)
3.4.3 COVID Impact Market Analysis (U-Shaped Recovery Scenario)
3.4.4 COVID Impact Market Analysis (L-Shaped Recovery Scenario)
3.5 Porter’s Five Forces Analysis
3.5.1 Supplier Power
3.5.2 Buyer Power
3.5.3 Competitive Rivalry
3.5.4 Threat from Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis
3.6.1 Political Factors
3.6.2 Economic Factors
3.6.3 Social Factors
3.6.4 Technological Factors

4 Direct-to-Patient Market Analysis by Type
4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Direct-to-Patient Marketing
4.4 Direct-to-Patient Health Services
4.5 Direct-to-Patient Clinical Trials
4.6 Direct-to-Patient Logistics
4.7 Direct-To-Patient Market by Type

5 Direct-To-Patient Market Analysis by Marketing
5.1 Key Findings
5.2 Marketing Segment: Market Attractiveness Index
5.3 DTC Prescribed Drug Advertising
5.4 Disease Awareness Campaigns
5.5 Brand Promotion
5.6 Healthcare Services Promotion
5.7 Laboratory Testing Promotion
5.8 Other Direct-to-Patient Marketing
5.9 Direct-to-Patient Market by Marketing

6 Direct-to-Patient Market Analysis by Direct-to-Patient Health Services
6.1 Key Findings
6.2 Direct-to-Patient Health Services Segment: Market Attractiveness Index
6.3 Tele Consultation
6.4 Drug Prescription
6.5 Medical Call Centers
6.6 Telesampling
6.7 Online Services
6.8 Direct-to-Patient Market by Health Service

7 Direct-to-Patient Market Analysis by Clinical Trials
7.1 Key Findings
7.2 Clinical Trials Segment: Market Attractiveness Index
7.3 Tele Health Screening
7.4 Investigational Medicinal Product (IMP)
7.5 Patient Support Systems
7.6 Other Clinical Trial Services
7.7 Direct-to-Patient Market by Clinical Trials

8 Direct-to-Patient Market Analysis by Direct-to-Patient Logistics
8.1 Key Findings
8.2 Direct-to-Patient Logistics Segment: Market Attractiveness Index
8.3 Prescribed Medicine Delivery
8.4 Pre-Clinical Supplies
8.5 Clinical Trial Supplies
8.6 Home Trial Support
8.7 Test Samples Collection
8.8 Direct-to-Patient Market by Logistics

9 Direct-to-Patient Market Analysis by Therapeutics
9.1 Key Findings
9.2 Therapeutics Segment: Market Attractiveness Index
9.3 Cardiovascular Diseases
9.4 Respiratory Diseases
9.5 Oncology
9.6 Infectious Diseases
9.7 Dermatology
9.8 Other Therapeutics
9.9 Direct-to-Patient Market by Therapeutics
10 Direct-to-Patient Market Analysis by Model
10.1 Key Findings
10.2 Model Segment: Market Attractiveness Index
10.3 Site-to-Patient
10.4 Hybrid Model
10.5 Direct-From-Patient (DfP)
10.6 Other DtP Models
10.7 Direct-to-Patient Market by Model

11 Direct-to-Patient Market Analysis by Region
11.1 Key Findings
11.2 Direct-to-Patient Market Attractiveness Index by Region
11.3 Direct-to-Patient Market Forecast
11.4 Direct-to-Patient Market by Region

12 North America Direct-To-Patient Market Analysis
12.1 Key Findings
12.2 Growing Desire for In-Home Care
12.3 Multinational DtP Company Presence in the Region
12.4 North America Direct-To-Patient Market Attractiveness Index by Region
12.5 Direct-to-Patient Market by Value
12.6 North America Direct-to-Patient Market by Marketing
12.7 North America Direct-to-Patient Market by Health Services
12.8 North America Direct-to-Patient Market by Clinical Trials
12.9 North America Direct-to-Patient Market by Logistics
12.10 North America Direct-to-Patient Market by Therapeutics
12.11 North America Direct-to-Patient Market by Model
12.12 North America Direct-to-Patient Market by Country
12.13 U.S. Direct-to-Patient Market Analysis
12.13.1 Rising Healthcare Costs Are Anticipated to Accelerate the Uptake of Telehealth
12.13.2 U.S. Laws for DTP Businesses
12.14 Canada Direct-to-Patient Market Analysis
12.14.1 Increasing Preference for Remote and Home Monitoring

13 Europe Direct-To-Patient Market Analysis
13.1 Key Findings
13.2 Significant Investment in Clinical Research Infrastructure
13.3 How DtP Supports Clinical Trial Innovation?
13.4 Europe Direct-to-Patient Market Attractiveness Index by Region
13.5 Europe Direct-to-Patient Market by Value
13.6 Europe Direct-to-Patient Market by Type
13.7 Europe Direct-to-Patient Market by Marketing
13.8 Europe Direct-to-Patient Market by Health Services
13.9 Europe Direct-to-Patient Market by Clinical Trials
13.10 Europe Direct-to-Patient Market by Logistics
13.11 Europe Direct-to-Patient Market by Therapeutics
13.12 Europe Direct-to-Patient Market by Model
13.13 Europe Direct-to-Patient Market by Country
13.14 Germany Direct-To-Patient Market Analysis
13.14.1 Germany's DTP Market Growing Due to Good Health Reimbursement Policies
13.14.2 Numerous Telemedicine Systems Are Now in Use
13.15 U.K. Direct-To-Patient Market Analysis
13.15.1 Hospital-based Care Trend Shifting to Home Care
13.15.2 Ageing Population Will Bring Opportunities for DTP
13.16 France Direct-To-Patient Market Analysis
13.16.1 Significant Fragmentation in the Direct-to-Patient Services Market
13.17 Italy Direct-to-Patient Market Analysis
13.17.1 Quality and Effectiveness of the Italian Healthcare System Can Occasionally Be Criticised
13.17.2 Laws Concerning the Delivery of DTP Services
13.18 Spain Direct-To-Patient Market Analysis
13.18.1 The Healthcare System in Spain is Among the Best in the World
13.19 Rest of Europe Direct-To-Patient Market Analysis

14 Asia-Pacific Direct-To-Patient Market Analysis
14.1 Key Findings
14.2 Growing Health Consumerism
14.3 A Shift in Stakeholder Confidence
14.4 Asia Pacific Direct-to-Patient Market Attractiveness Index by Region
14.5 Asia Pacific Direct-to-Patient Market by Value
14.6 Asia Pacific Direct-to-Patient Market by Type
14.7 Asia Pacific Direct-to-Patient Market by Marketing
14.8 Asia Pacific Direct-to-Patient Market by Health Services
14.9 Asia Pacific Direct-to-Patient Market by Clinical Trials
14.10 Asia Pacific Direct-to-Patient Market by Logistics
14.11 Asia Pacific Direct-to-Patient Market by Therapeutics
14.12 Asia Pacific Direct-to-Patient Market by Model
14.13 Asia Pacific Direct-to-Patient Market by Country
14.14 China Direct-to-Patient Market Analysis
14.14.1 Government Made "Direct-To-Patients" Shipment of Investigational Drugs Mandatory
14.15 India Direct-to-Patient Market Analysis
14.15.1 Country's Healthcare System is Transitioning to the DtP Model
14.15.2 Telemedicine in India
14.16 Japan Direct-to-Patient Market Analysis
14.16.1 DtP Services Are Becoming More Popular in Japan
14.16.2 Close Patient Engagement is a Majorly Emerging Sector for Japanese Pharma
14.17 Australia Direct-to-Patient Market Analysis
14.17.1 Australian Government Offers Packages for Home Care Package (HCP)
14.17.2 Remarkable Growth of Australia's Market for Direct-To-Patient
14.18 South Korea Direct-to-Patient Market Analysis
14.19 Rest of Asia-Pacific Direct-to-Patient Market Analysis

15 Latin America Direct-To-Patient Market Analysis
15.1 Key Findings
15.2 Latin America Direct-to-Patient Market Attractiveness Index by Region
15.3 Latin America Direct-To-Patient Market by Value
15.4 Latin America Direct-To-Patient Market by Type
15.5 Latin America Direct-To-Patient Market by Marketing
15.6 Latin America Direct-To-Patient Market by Health Services
15.7 Latin America Direct-To-Patient Market by Clinical Trials
15.8 Latin America Direct-To-Patient Market by Logistics
15.9 Latin America Direct-To-Patient Market by Therapeutics
15.10 Latin America Direct-To-Patient Market by Model
15.11 Latin America Direct-To-Patient Market by Country
15.12 Brazil Direct-to-Patient Market Analysis
15.12.1 Government Policies for the DTP Industry
15.13 Mexico Direct-to-Patient Market Analysis
15.14 Rest of Latin America Direct-to-Patient Market Analysis

16 MEA Direct-To-Patient Market Analysis
16.1 Key Findings
16.2 MEA Direct-to-Patient Market Attractiveness Index by Region
16.3 MEA Direct-To-Patient Market by Value
16.4 MEA Direct-To-Patient Market by Type
16.5 MEA Direct-To-Patient Market by Marketing
16.6 MEA Direct-To-Patient Market by Health Services
16.7 MEA Direct-To-Patient Market by Clinical Trials
16.8 MEA Direct-To-Patient Market by Logistics
16.9 MEA Direct-To-Patient Market by Therapeutics
16.10 MEA Direct-To-Patient Market by Model
16.11 MEA Direct-To-Patient Market by Country
16.12 Saudi Arabia Direct-to-Patient Market Analysis
16.12.1 Saudi Arabia Government is Developing and Improving Healthcare Services Through a Transformation Plan
16.13 Turkey Direct-to-Patient Market Analysis
16.13.1 Direct To Patient Has a Large Distribution Network that Reaches All Regions of Turkey
16.13.2 Turkey’s Family Medicine Reform Will Boost Demand for DtP Services in Nearing Future
16.14 UAE Direct-to-Patient Market Analysis
16.14.1 Rise in Healthcare Demand in the United Arab Emirates
16.14.2 UAE is Moving Toward DtP and Telehealth Models
16.15 South Africa Direct-to-Patient Market Analysis
16.15.1 Professional Training is Required for DtP Service Providers
16.15.2 Patient's Cultural and Family Context at Home Must Include Professional DTP
16.16 Rest of MEA Direct-to-Patient Market Analysis
16.16.1 Start-Ups in the Nation Could Destabilise the DTP Market

17 Competitive Landscape
17.1 Key Business Strategy Analysis- Agreement
17.2 Key Business Strategy Analysis- Contract
17.3 Key Business Strategy Analysis- Expansion
17.4 Key Business Strategy Analysis- Partnership
17.5 Key Business Strategy Analysis- Launch

18 Company Profiles
18.1 Access TeleCare
18.1.1 Company Snapshot
18.1.2 Company Overview
18.1.3 Product Benchmarking
18.1.4 Strategic Outlook
18.2 Agnity Inc.
18.2.1 Company Snapshot
18.2.2 Company Overview
18.2.3 Product Benchmarking
18.2.4 Strategic Outlook
18.3 AMD Global Telemedicine
18.3.1 Company Snapshot
18.3.2 Company Overview
18.3.3 Product Benchmarking
18.3.4 Strategic Outlook
18.4 American Well
18.4.1 Company Snapshot
18.4.2 Company Overview
18.4.3 Financial Analysis
18.4.3.1 Net Revenue, 2018-2021
18.4.3.2 Operating Income, 2018-2021
18.4.3.3 Research & Development Expenses, 2018-2021
18.4.4 Product Benchmarking
18.4.5 Strategic Outlook
18.5 Avel eCare
18.5.1 Company Snapshot
18.5.2 Company Overview
18.5.3 Product Benchmarking
18.5.4 Strategic Outlook
18.6 Axs Health
18.6.1 Company Snapshot
18.6.2 Company Overview
18.6.3 Product Benchmarking
18.6.4 Strategic Outlook
18.7 Babylon Health
18.7.1 Company Snapshot
18.7.2 Company Overview
18.7.2.1 Net Revenue, 2019-2021
18.7.2.2 Operating Income, 2019-2021
18.7.2.3 R&D Expenses, 2019-2021
18.7.3 Product Benchmarking
18.7.4 Strategic Outlook
18.8 Citius Tech
18.8.1 Company Snapshot
18.8.2 Company Overview
18.8.3 Product Benchmarking
18.8.4 Strategic Outlook
18.9 Dictum Health Inc.
18.9.1 Company Snapshot
18.9.2 Company Overview
18.9.3 Product Benchmarking
18.9.4 Strategic Outlook
18.10 Doctor Anywhere
18.10.1 Company Snapshot
18.10.2 Company Overview
18.10.3 Product Benchmarking
18.10.4 Strategic Outlook
18.11 Doctor on Demand
18.11.1 Company Snapshot
18.11.2 Company Overview
18.11.3 Product Benchmarking
18.11.4 Strategic Outlook
18.12 Health Partners
18.12.1 Company Snapshot
18.12.2 Company Overview
18.12.3 Financial Analysis
18.12.3.1 Net Revenue, 2018-2020
18.12.3.2 Operating Income, 2018-2020
18.12.4 Product Benchmarking
18.12.5 Strategic Outlook
18.13 Health Tap
18.13.1 Company Snapshot
18.13.2 Company Overview
18.13.3 Product Benchmarking
18.13.4 Strategic Outlook
18.14 HIMS
18.14.1 Company Snapshot
18.14.2 Company Overview
18.14.3 Financial Analysis
18.14.3.1 Net Revenue, 2019-2021
18.14.3.2 Operating Income, 2019-2021
18.14.4 Product Benchmarking
18.14.5 Strategic Outlook
18.15 Marken
18.15.1 Company Snapshot
18.15.2 Company Overview
18.15.3 Product Benchmarking
18.15.4 Strategic Outlook
18.16 20/20 NOW
18.16.1 Company Snapshot
18.16.2 Company Overview
18.16.3 Product Benchmarking
18.16.4 Strategic Outlook
18.17 NURX
18.17.1 Company Snapshot
18.17.2 Company Overview
18.17.3 Product Benchmarking
18.17.4 Strategic Outlook
18.18 Practo Technologies Pvt. Ltd
18.18.1 Company Snapshot
18.18.2 Company Overview
18.18.3 Product Benchmarking
18.18.4 Strategic Outlook
18.19 Specialists on call, Inc
18.19.1 Company Snapshot
18.19.2 Company Overview
18.19.3 Financial Analysis
18.19.3.1 Net Revenue, 2019-2021
18.19.3.2 Research & Development Expense, 2019-2021
18.19.4 Product Benchmarking
18.19.5 Strategic Outlook
18.20 Teladoc Health Inc
18.20.1 Company Snapshot
18.20.2 Company Overview
18.20.3 Financial Analysis
18.20.3.1 Net Revenue, 2017-2021
18.20.3.2 Operating Income, 2017-2021
18.20.3.3 Research & Development Expenses, 2017-2021
18.20.4 Product Benchmarking
18.20.5 Strategic Outlook
18.21 True pill
18.21.1 Company Snapshot
18.21.2 Company Overview
18.21.3 Product Benchmarking
18.21.4 Strategic Outlook
18.22 Up Script Health
18.22.1 Company Snapshot
18.22.2 Company Overview
18.22.3 Product Benchmarking
18.22.4 Strategic Outlook

19 Conclusion and Recommendations
19.1 Concluding Remarks from Visiongain
19.2 Recommendations for Market Players

List of Tables
Table 1 Direct-to-Patient Market Snapshot, 2022 & 2032 (US$ million, CAGR %)
Table 2 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario)
Table 3 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario)
Table 4 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario)
Table 5 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario)
Table 6 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario)
Table 7 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario)
Table 8 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario)
Table 9 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario)
Table 10 Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 11 Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 12 Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 13 Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 14 Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 15 Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 16 Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 17 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 18 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 19 North America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 20 North America Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 21 North America Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 22 North America Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 23 North America Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 24 North America Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 25 North America Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 26 North America Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 27 U.S. Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 28 Canada Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 29 Europe Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 30 Europe Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 31 Europe Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 32 Europe Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 33 Europe Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 34 Europe Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 35 Europe Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 36 Europe Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 37 Europe Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 38 Germany Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 39 UK Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 40 France Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 41 Italy Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 42 Spain Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 43 Rest of Europe Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 44 Asia-Pacific Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 45 Asia-Pacific Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 46 Asia-Pacific Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 47 Asia-Pacific Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 48 Asia-Pacific Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 49 Asia-Pacific Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 50 Asia-Pacific Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 51 Asia-Pacific Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 52 Asia-Pacific Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 53 China Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 54 India Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 55 Japan Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 56 Australia Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 57 South Korea Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 58 Rest of Asia-Pacific Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 59 Latin America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 60 Latin America Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 61 Latin America Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 62 Latin America Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 63 Latin America Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 64 Latin America Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 65 Latin America Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 66 Latin America Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 67 Latin America Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 68 Brazil Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 69 Mexico Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 70 Rest of Latin America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR(%))
Table 71 MEA Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 72 MEA Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 73 MEA Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 74 MEA Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 75 MEA Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 76 MEA Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 77 MEA Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 78 MEA Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 79 MEA Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 80 Saudi Arabia Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 81 Turkey Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 82 UAE Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 83 South Africa Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 84 Rest of MEA Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%), CAGR (%))
Table 85 Agreement As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market
Table 86 Contract As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market
Table 87 Expansion As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market
Table 88 Partnership As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market
Table 89 Launch As Key Business Strategies Adopted by Key Players in Direct-to-Patient Market
Table 90 Access TeleCare: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Access Telecare, .: Product Benchmarking
Table 92 Access TeleCare, .: Strategic Outlook
Table 93 AGNITY INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 AGNITY INC.: Product Benchmarking
Table 95 AGNITY INC.: Strategic Outlook
Table 96 AMD Global Telemedicine: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 AMD Global Telemedicine: Product Benchmarking
Table 98 AMD Global Telemedicine: Strategic Outlook
Table 99 American Well: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 American Well: Product Benchmarking
Table 101 American Well: Strategic Outlook
Table 102 Avel eCare: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Avera e Care: Product Benchmarking
Table 104 Avera e Care: Strategic Outlook
Table 105 Axs Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Axs Health: Product Benchmarking
Table 107 Axs Healthcare: Strategic Outlook
Table 108 Babylon Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 Babylon Health: Product Benchmarking
Table 110 Babylon Health: Strategic Outlook
Table 111 Citius Tech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Citius Tech: Product Benchmarking
Table 113 Citius Tech: Strategic Outlook
Table 114 Dictum Health Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Dictum Health Inc: Product Benchmarking
Table 116 Dictum Health Inc: Strategic Outlook
Table 117 Doctor Anywhere: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Doctor Anywhere: Product Benchmarking
Table 119 Doctor Anywhere: Strategic Outlook
Table 120 Doctor on demand: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 121 Doctor on demand: Product Benchmarking
Table 122 Doctor on demand: Strategic Outlook
Table 123 Health Partners: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Health Partners: Product Benchmarking
Table 125 Health Partners: Strategic Outlook
Table 126 Health Tap: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 127 Health Tap: Product Benchmarking
Table 128 Health Tap: Strategic Outlook
Table 129 HIMS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 130 HIMS: Product Benchmarking
Table 131 HIMS: Strategic Outlook
Table 132 Marken: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 Marken: Product Benchmarking
Table 134 Marken: Strategic Outlook
Table 135 20/20 NOW: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 136 20/20 NOW: Product Benchmarking
Table 137 20/20 NOW: Strategic Outlook
Table 138 NURX: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 NURX: Product Benchmarking
Table 140 NURX: Strategic Outlook
Table 141 Practo Technologies Pvt. Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 142 Practo Technologies Pvt Ltd: Product Benchmarking
Table 143 Practo Technologies Pvt Ltd: Strategic Outlook
Table 144 Specialists on call, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 145 Specialists on call, Inc: Product Benchmarking
Table 146 Specialists on call, Inc: Strategic Outlook
Table 147 Teladoc Health Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 148 Teladoc Health Inc: Product Benchmarking
Table 149 Teladoc Health Inc: Strategic Outlook
Table 150 True pill: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 151 True pill: Product Benchmarking
Table 152 True pill: Strategic Outlook
Table 153 Up Script Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 154 Up Script Health: Product Benchmarking
Table 155 Up Script Health: Strategic Outlook

List of Figures
Figure 1 Schematics showing benefits of Direct-To-Patient Model
Figure 2 Direct-to-Patient Market Segmentation
Figure 3 Direct-to-Patient Market Forecast by Region: Market Attractiveness Index
Figure 4 Direct-to-Patient Market by Type: Market Attractiveness Index
Figure 5 Direct-to-Patient Market by Marketing: Market Attractiveness Index
Figure 6 Direct-to-Patient Market by Health Services: Market Attractiveness Index
Figure 7 Direct-to-Patient Market by Clinical Trials: Market Attractiveness Index
Figure 8 Direct-to-Patient Market by Logistics: Market Attractiveness Index
Figure 9 Direct-to-Patient Market by Therapeutics: Market Attractiveness Index
Figure 10 Direct-to-Patient Market by Model: Market Attractiveness Index
Figure 11 Direct-to-Patient Market: Market Dynamics
Figure 12 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario)
Figure 13 Direct-to-Patient Market Forecast by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (V-Shaped Recovery Scenario)
Figure 14 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario)
Figure 15 Direct-to-Patient Market Forecast by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (W-Shaped Recovery Scenario)
Figure 16 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario)
Figure 17 Direct-to-Patient Market Forecast by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (U-Shaped Recovery Scenario)
Figure 18 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario)
Figure 19 Direct-to-Patient Market Forecast by Region, 2022-2032 (US$ Mn, AGR (%), CAGR (%)) (L-Shaped Recovery Scenario)
Figure 20 Direct-to-Patient Market: Porter’s Five Forces Analysis
Figure 21 Direct-to-Patient Market: PEST Analysis
Figure 22 Direct-To-Patient Market by Type: Market Attractiveness Index
Figure 23 Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%)
Figure 24 Direct-To-Patient Market by Marketing: Market Attractiveness Index
Figure 25 Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%))
Figure 26 Direct-to-Patient Market Forecast by Direct-to-Patient Health Services: Market Attractiveness Index
Figure 27 Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%))
Figure 28 Direct-to-Patient Market Forecast by Clinical Trials: Market Attractiveness Index
Figure 29 Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%))
Figure 30 Direct-To-Patient Market Forecast by Direct-to-Patient Logistics: Market Attractiveness Index
Figure 31 Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%))
Figure 32 Direct-to-Patient Market Forecast by Therapeutics: Market Attractiveness Index
Figure 33 Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%)
Figure 34 Direct-to-Patient Market Forecast by Model: Market Attractiveness Index
Figure 35 Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%)
Figure 36 Direct-to-Patient Market Attractiveness Index by Region: Market Attractiveness Index
Figure 37 Direct-to-Patient Market Forecast, 2022-2032 (US$ Mn, AGR (%))
Figure 38 Direct-to-Patient Market by Region, 2022-2032 (US$ Mn, AGR (%))
Figure 39 Direct-to-Patient Market Attractiveness Index by Region 2022, 2032 (Revenue, CAGR%)
Figure 40 North America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 41 North America Direct-to-Patient Market Share Forecast by Type 2022-2033 (%)
Figure 42 North America Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR %)
Figure 43 North America Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%)
Figure 44 North America Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%))
Figure 45 North America Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%)
Figure 46 North America Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%))
Figure 47 North America Direct-to-Patient Market Share Forecast by Clinical Trial 2023-2033 (%)
Figure 48 North America Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%))
Figure 49 North America Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%)
Figure 50 North America Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR %)
Figure 51 North America Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%)
Figure 52 North America Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%))
Figure 53 North America Direct-to-Patient Market Share Forecast by Model 2023-2033 (%)
Figure 54 North America Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%))
Figure 55 North America Direct-to-Patient Market Share Forecast by Country 2023-2033 (%)
Figure 56 U.S. Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 57 Canada Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 58 Europe Direct-to-Patient Market Attractiveness Index by Region
Figure 59 Europe Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 60 Europe Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%))
Figure 61 Europe Direct-to-Patient Market Share Forecast by Type 2022-2032 (%)
Figure 62 Europe Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%))
Figure 63 Europe Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%)
Figure 64 Europe Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%))
Figure 65 Europe Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%)
Figure 66 Europe Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%))
Figure 67 Europe Direct-to-Patient Market Share Forecast by Clinical Trials 2022-2032 (%)
Figure 68 Europe Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%))
Figure 69 Europe Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%)
Figure 70 Europe Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%))
Figure 71 Europe Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%)
Figure 72 Europe Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%))
Figure 73 Europe Direct-to-Patient Market Share Forecast by Model 2022-2032 (%)
Figure 74 Europe Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%))
Figure 75 Europe Direct-to-Patient Market Share Forecast by Country 2022-2032 (%)
Figure 76 Germany Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 77 UK Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 78 France Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 79 Italy Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 80 Spain Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 81 Rest of Europe Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 82 Asia Pacific Direct-to-Patient Market Attractiveness Index by Region
Figure 83 Asia-Pacific Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 84 Asia-Pacific Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR %))
Figure 85 Asia Pacific Direct-to-Patient Market Share Forecast by Type 2022-2032 (%)
Figure 86 Asia-Pacific Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%))
Figure 87 Asia Pacific Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%)
Figure 88 Asia-Pacific Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%))
Figure 89 Asia Pacific Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%)
Figure 90 Asia-Pacific Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%))
Figure 91 Asia Pacific Direct-to-Patient Market Share Forecast by Clinical Trials 2022-2032 (%)
Figure 92 Asia-Pacific Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%))
Figure 93 Asia Pacific Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%)
Figure 94 Asia-Pacific Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%))
Figure 95 Asia Pacific Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%)
Figure 96 Asia-Pacific Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%))
Figure 97 Asia Pacific Direct-to-Patient Market Share Forecast by Models 2022-2032 (%)
Figure 98 Asia-Pacific Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR %))
Figure 99 Asia Pacific Direct-to-Patient Market Share Forecast by Country 2023-2033 (%)
Figure 100 China Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 101 India Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 102 Japan Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 103 Australia Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 104 South Korea Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 105 Rest of Asia-Pacific Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 106 Latin America Direct-to-Patient Market Attractiveness Index by Region
Figure 107 Latin America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 108 Latin America Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%))
Figure 109 Latin America Direct-to-Patient Market Share Forecast by Type 2022-2032 (%)
Figure 110 Latin America Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%))
Figure 111 Latin America Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%)
Figure 112 Latin America Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%))
Figure 113 Latin America Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%)
Figure 114 Latin America Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%))
Figure 115 Latin America Direct-to-Patient Market Share Forecast by Clinical Trials 2022-2032 (%)
Figure 116 Latin America Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%))
Figure 117 Latin America Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%)
Figure 118 Latin America Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%))
Figure 119 Latin America Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%)
Figure 120 Latin America Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%))
Figure 121 Latin America Direct-to-Patient Market Share Forecast by Model 2023-2033 (%)
Figure 122 Latin America Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%))
Figure 123 Latin America Direct-to-Patient Market Share Forecast by country 2023-2033 (%)
Figure 124 Brazil Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 125 Mexico Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 126 Rest of Latin America Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 127 MEA Direct-to-Patient Market Attractiveness Index by Region
Figure 128 MEA Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 129 MEA Direct-to-Patient Market by Type, 2022-2032 (US$ Mn, AGR (%))
Figure 130 MEA Direct-to-Patient Market Share Forecast by Type 2022-2032 (%)
Figure 131 MEA Direct-to-Patient Market by Marketing, 2022-2032 (US$ Mn, AGR (%))
Figure 132 MEA Direct-to-Patient Market Share Forecast by Marketing 2022-2032 (%)
Figure 133 MEA Direct-to-Patient Market by Health Services, 2022-2032 (US$ Mn, AGR (%))
Figure 134 MEA Direct-to-Patient Market Share Forecast by Health Services 2022-2032 (%)
Figure 135 MEA Direct-to-Patient Market by Clinical Trials, 2022-2032 (US$ Mn, AGR (%))
Figure 136 MEA Direct-to-Patient Market Share Forecast by Clinical Trial 2022-2032 (%)
Figure 137 MEA Direct-to-Patient Market Logistics, 2022-2032 (US$ Mn, AGR (%))
Figure 138 MEA Direct-to-Patient Market Share Forecast by Logistics 2022-2032 (%)
Figure 139 MEA Direct-to-Patient Market by Therapeutics, 2022-2032 (US$ Mn, AGR (%))
Figure 140 MEA Direct-to-Patient Market Share Forecast by Therapeutics 2022-2032 (%)
Figure 141 MEA Direct-to-Patient Market by Model, 2022-2032 (US$ Mn, AGR (%))
Figure 142 MEA Direct-to-Patient Market Share Forecast by Model 2022-2032 (%)
Figure 143 MEA Direct-to-Patient Market by Country, 2022-2032 (US$ Mn, AGR (%))
Figure 144 MEA Direct-to-Patient Market Share Forecast by Country 2022-2032 (%)
Figure 145 Saudi Arabia Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 146 Turkey Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 147 UAE Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 148 South Africa Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 149 Rest of MEA Direct-to-Patient Market by Value, 2022-2032 (US$ Mn, AGR (%))
Figure 150 American Well: Net Revenue, 2018-2021 (US$ million, AGR (%))
Figure 151 American Well: Operating Income 2018-2021 (US$ million, AGR (%))
Figure 152 American Well: Research & Development Expenses 2018-2021 (US$ million, AGR (%))
Figure 153 Babylon Health: Net Revenue, 2019-2021 (US$ million, AGR%)
Figure 154 Babylon Health: Operating Income, 2019-2021 (US$ million, AGR%)
Figure 155 Babylon Health: R&D Expenses 2019-2021 (US$ million, AGR%)
Figure 156 Health Partners: Net Revenue, 2018-2020 (US$ million, AGR (%))
Figure 157 Health Partners: Operating Income, 2018-2020 (US$ million, AGR (%))
Figure 158 HIMS: Net Revenue, 2019-2021 (US$ million, AGR (%))
Figure 159 HIMS: R&D Expenses, 2019-2021 (US$ million, AGR (%))
Figure 160 Specialists on call, Inc: Revenue, 2019-2021 (US$ million, AGR (%))
Figure 161 Specialists on call, Inc: R&D Expense 2019-2021 (US$ million, AGR%)
Figure 162 Teladoc, Health Inc: Revenue, 2017-2021 (US$ million, AGR (%))
Figure 163 Teladoc, Health Inc: Operating Income, 2017-2021 (US$ million, AGR(%))
Figure 164 Teladoc, Health Inc Research & Development Expenses 2017-2021 (US$ million, AGR (%))